The impact of reference-pricing systems in Europe: a literature review and case studies

As healthcare budgets are continuously rising in Europe, governments implement a wide variety of policies to control them. Reference pricing is a popular tool for governments to contain pharmaceutical expenditures, as 22 European countries have implemented this system. This article evaluates the impact of reference-pricing systems on drug use, drug prices, drug expenditure and health outcomes. In addition, two case studies, one for statins and one for proton-pump inhibitors, were carried out. Reference pricing drives down prices of drugs subject to the system and the use of these drugs has increased. Reference pricing creates short-term savings but the long-term growth of drug expenditure has not been reduced by reference pricing. Health outcomes of patients were not negatively affected by the system.

[1]  J. McNeil,et al.  Reference-Based Pricing Schemes , 2012, PharmacoEconomics.

[2]  S. Simoens,et al.  Pharmaceutical policy regarding generic drugs in Belgium , 2012, PharmacoEconomics.

[3]  M. Miraldo,et al.  Effects of Reference Pricing in Pharmaceutical Markets , 2012, PharmacoEconomics.

[4]  J. Puig-Junoy,et al.  Do generic firms and the Spanish public purchaser respond to consumer price differences of generics under reference pricing? , 2010, Health policy.

[5]  A. Vulto,et al.  The social value of innovation , 2010 .

[6]  S. Simoens,et al.  Generic Medicine Pricing Policies in Europe: Current Status and Impact , 2010, Pharmaceuticals.

[7]  S. Simoens,et al.  A call to make valuable innovative medicines available in the European Union , 2010 .

[8]  T. Stargardt.  The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany , 2010, The European Journal of Health Economics.

[9]  Helle Håkonsen,et al.  Price control as a strategy for pharmaceutical cost containment - what has been achieved in Norway in the period 1994-2004? , 2009, Health policy.

[10]  J. Wasem,et al.  Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach. , 2009, Health economics.

[11]  Joan Costa-Font,et al.  Competition in Off-Patent Drug Markets: Issues, Regulation and Evidence , 2008 .

[12]  J. Puig-Junoy.  The impact of generic reference pricing interventions in the statin market. , 2007, Health policy.

[13]  Kurt R. Brekke,et al.  Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation? , 2007, SSRN Electronic Journal.

[14]  S. Schneeweiss.  Reference drug programs: effectiveness and policy implications. , 2007, Health policy.

[15]  N. Muszbek,et al.  Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. , 2007, Health policy.

[16]  Sajjad Ahmad,et al.  Limiting youth access to tobacco: comparing the long-term health impacts of increasing cigarette excise taxes and raising the legal smoking age to 21 in the United States. , 2007, Health policy.

[17]  F. Fernandez‐Llimos,et al.  Antidepressant utilization in primary care in a Spanish region , 2007, Social Psychiatry and Psychiatric Epidemiology.

[18]  K. Nowicka.  Innovation in the Pharmaceutical Sector , 2006 .

[19]  M. Petzold,et al.  Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002. , 2006, Health policy.

[20]  S. Simoens,et al.  Sustaining Generic Medicines Markets in Europe , 2006 .

[21]  Marten Postma,et al.  Switch patterns before and after patent expiry of omeprazole: a case study in The Netherlands , 2006, Alimentary pharmacology & therapeutics.

[22]  L. Garattini,et al.  Off-patent drugs in Italy. A short-sighted view? , 2006, The European journal of health economics : HEPAC : health economics in prevention and care.

[23]  L. Garattini,et al.  Off-patent drugs in Italy , 2006, The European Journal of Health Economics.

[24]  I. Krulichová,et al.  Pharmaceutical policy in Italy: towards a structural change? , 2005, Health policy.

[25]  P. Danzon,et al.  Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands, and New Zealand , 2003, Frontiers in health policy research.

[26]  J. Mestre-Ferrandiz.  Reference Prices and Generic Medicines: What Can We Expect? , 2003 .

[27]  S. Schneeweiss,et al.  Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers , 2003, Clinical pharmacology and therapeutics.

[28]  M. Koopmanschap,et al.  The drug budget silo mentality: the Dutch case. , 2003, Value in Health.

[29]  Nina Pavcnik.  Do pharmaceutical prices respond to potential patient out-of-pocket expenses? , 2002 .

[30]  S. Schneeweiss,et al.  Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. , 2002, The New England journal of medicine.

[31]  B. O'brien,et al.  The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia -- Volume II: Technical Report , 2002 .

[32]  J. McNeil,et al.  Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. , 2002, PharmacoEconomics.

[33]  Nina Pavenik,et al.  Do pharmaceutical prices respond to potential patient out-of-pocket expenses? , 2002, The Rand journal of economics.

[34]  J. Puig-Junoy,et al.  Review of the literature on reference pricing. , 2000, Health policy.

[35]  A. Guhl.  Pricing and Reimbursement Systems in Europe , 2000, HEPAC Health Economics in Prevention and Care.

[36]  G. Selke,et al.  The German experience in reference pricing. , 1998, Health policy.